Modeling was based on parameters derived from imaging data, measured in vitro, or already reported, including circulating half-life, lipophilicity, plasma protein binding, tumor vascularity, on-target (BRAF) association and dissociation, and others; in some cases, parameters were estimated from model compounds (tables S2 to S4; details in the Supplementary Materials). The gene discussed is BRAF; the disease is neoplasm.